Scholarlink

<p>Myocardial infarction (MI) remains a leading cause of global mortality, with the immune and coagulation systems playing pivotal roles in its pathophysiology. This study aimed to identify biomarkers associated with immune-related genes (IRGs) and coagulation-related genes (CRGs) in MI and to explore their potential regulatory mechanisms in treatment. Data from the GSE61144 and GSE60993 datasets were utilized. Four genes (IGF2R, TGFA, PLAUR, and MAPK14) were identified, exhibiting significantly elevated serum levels in patients with MI. Their distribution across tissues and single cells was further analyzed. Methylation site analysis of the N6-methyladenosine (m<sup>6</sup>A) biomarker revealed high-confidence methylation sites in IGF2R, PLAUR, and MAPK14. The RNA-binding protein (RBP) interactions were examined, revealing high-affinity binding sites for TARDBP in both IGF2R and MAPK14. GeneMANIA analysis highlighted biomarker-associated genes enriched in positive kinase regulation. Furthermore, a total of 20 potential drugs were predicted, with albuterol sulfate identified as a target for IGF2R, and molecular docking confirming the strongest binding affinity in the IGF2R-albuterol sulfate complex.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring biomarkers related to coagulation and immunity in myocardial infarction based on bioinformatics

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月19日

查看全文
  • Jiwen Liu,
  • Xuemei Chen,
  • Xinmeichen Meng,
  • Hui Huang,
  • Jun Zhao,
  • Zeyi Cheng,
  • Lu Zhang,
  • Junling Huang,
  • Dongfeng Guo,
  • Xiaoyan Yuan

摘要

Myocardial infarction (MI) remains a leading cause of global mortality, with the immune and coagulation systems playing pivotal roles in its pathophysiology. This study aimed to identify biomarkers associated with immune-related genes (IRGs) and coagulation-related genes (CRGs) in MI and to explore their potential regulatory mechanisms in treatment. Data from the GSE61144 and GSE60993 datasets were utilized. Four genes (IGF2R, TGFA, PLAUR, and MAPK14) were identified, exhibiting significantly elevated serum levels in patients with MI. Their distribution across tissues and single cells was further analyzed. Methylation site analysis of the N6-methyladenosine (m6A) biomarker revealed high-confidence methylation sites in IGF2R, PLAUR, and MAPK14. The RNA-binding protein (RBP) interactions were examined, revealing high-affinity binding sites for TARDBP in both IGF2R and MAPK14. GeneMANIA analysis highlighted biomarker-associated genes enriched in positive kinase regulation. Furthermore, a total of 20 potential drugs were predicted, with albuterol sulfate identified as a target for IGF2R, and molecular docking confirming the strongest binding affinity in the IGF2R-albuterol sulfate complex.